Abacus Bioscience is focused on developing first-in-class active immunotherapies designed to overcome immune tolerance, specifically targeting cancer and chronic infections. Their innovative approach aims to extend the capabilities of immunotherapy, which is a critical area in oncology. The company leverages advanced scientific insights, including structural predictions of their experimental drugs, as exemplified by the use of AlphaFold technology, to enhance the design and efficacy of their therapeutic candidates.

The leadership team at Abacus Bioscience boasts extensive experience in drug discovery and development, particularly in oncology and immunology. Key figures, such as Dr. Alan Wahl and Dr. Che-Leung Law, have contributed to the advancement of numerous experimental drug programs utilizing various therapeutic modalities, including T cells and engineered antibodies. Their combined expertise and a strong foundation in translational research position Abacus Bioscience to make significant strides in the field of immunotherapy, with a commitment to developing novel treatments that can effectively address complex diseases.

United States

Abacus Bioscience is developing a new class of immunotherapy that unleashes the power of a novel CD180 platform technology. 
Our Antigen-Specific Immune Accelerants (ASIA) are POTENT, SPECIFIC and DURABLE, with broad applications across infectious disease and oncology.

Abacus Bioscience

Company Details